Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2009-02-20
2011-10-11
Kifle, Bruck (Department: 1622)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
08034804
ABSTRACT:
The present invention relates to (pyrido/thieno)-[f]-oxazepine-5-one derivatives having the general Formula Iwherein R1, R2and R3are independently H or (C1-4)alkyl; Ar represents a fused thiophene or pyridine ring optionally substituted with one or more substituents selected from (C1-4)alkyl, (C1-4)alkyloxy, (C1-4)alkyloxy(C1-4)alkyl, CF3, halogen, nitro, cyano, NR4R5, NR4COR6, and CONR4R5; R4and R5are independently H or (C1-4)-alkyl; or R4and R5form together with the nitrogen atom to which they are bound a 5- or 6-membered saturated heterocyclic ring, optionally containing a further heteroatom selected from O, S or NR6; R6is (C1-4)alkyl; A represents the residue of a 4-7 membered saturated heterocyclic ring, optionally containing an oxygen atom, the ring being optionally substituted with 1-3 substituents selected from (C1-4)alkyl, (C1-4)-alkyloxy, hydroxy, halogen and oxo; or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising said derivatives, and to the use of these (pyrido/thieno)-[f]-oxazepine-5-one derivatives in the treatment of neurological diseases and psychiatric disorders which are responsive to enhancement of synaptic responses mediated by AMPA receptors in the central nervous system.
REFERENCES:
patent: 6174881 (2001-01-01), Borer et al.
patent: 19 54 839 (1970-05-01), None
patent: 0 884 310 (1998-12-01), None
patent: 1238719 (1971-07-01), None
patent: WO 94 02475 (1994-02-01), None
patent: WO 96 20941 (1996-07-01), None
patent: WO 96 38414 (1996-12-01), None
patent: WO 97 36907 (1997-10-01), None
patent: WO 99 33469 (1999-07-01), None
patent: WO 99 42456 (1999-08-01), None
patent: WO 99 51240 (1999-10-01), None
patent: WO00/68235 (2000-11-01), None
Alterman et al., “Fast Microwave-Assisted Preparation of Aryl and Vinyl Nitriles and the Corresponding Tetrazoles from Organo-halides,”J. Org. Chem. 65 (2000) 7984-7989.
Andrews et al., “Effects of imipramine and mirtazapine on operant performance in rats,”Drug Dev. Res. 32 (1994) 58-66.
Barn et al., “Synthesis of Novel Analogues of the Delta Opioid Ligand SNC-80 Using AICI3-Promoted Aminolysis,”Biorg. Med. Chem. Lett. 9 (1999)1329-34.
Bigge, C.F. et al., “AMPA receptor agaonists, antagonists and modulators: their potential for clinical utility”; Exp. Opin. Ther. Patents, vol. 7, No. 10, Oct. 1997, pp. 1099-1114.
Brown et al., “Selective Reductions. 30. Effect of Cation and Solvent on the Reactivity of Saline Borohydrides for Reduction of Carboxylic Esters. Improved Procedures for the Conversion of Esters to Alcohols by Metal Borohydrides,”J. Org. Chem. 47 (1982) 4702-4708.
Grove et al., “Positive Modulators of the AMPA Receptor,”Exp. Opin. Ther. Patents10 (2000) 1539-1548.
Hamill et al., “Improved Patch-Clamp Techniques for High-Resolution Current Recording from Cells and Cell-Free Membrane Patches,”Pflügers Arch. 391 (1981) 85-100.
Int'l Search Report, WO 02 100865 A1, Aug. 2, 2002.
International Search Report dated Dec. 18, 2002 for International Application No. PCT/EP2002/06364.
Ireland et al., “Application of the Swern Oxidation to the Manipulation of Highly Reactive Carbonyl Compounds,”J. Org. Chem. 50 (1985) 2198-2200.
Ito et al., “Allosteric Potentiation of Quisqualate Receptors by a Nootropic Drug Aniracetam,”J. Physiol. 424 (1990) 533-543.
Krapcho, A.P., et al. “Synthesis of Regioisomeric 6,9-(chlorofluoro)-Substituted Benzo[g]quinoline-5,10-diones, Benzo[g]isoquinoline-5,10-diones and 6-Chloro-9-fluorobenzo[g]quinoxaline-5,10-dione,”J. Het. Chem. 34 (1997) 27-31.
Lees, G.J., “Pharmacology of AMPA/Kainate Receptor Ligands and Their Therapeutic Potential in Neurological and Psychiatric Disorders,”Drugs59 (2000) 33-78.
Mitsunobu, O., “The Use of Diethyl Azodicarboxylate and Triphenylphosphine in Synthesis and Transformation of Natural Products,”Synthesis1 (1981), 1-28.
Olesen, Preben H., “The Use of Bioisosteric Groups in Lead Optimization,”Curr. Opin. Drug Discovery Dev. 4 (2001) 471-478.
Pasquier et al., “Free and Cr(CO)3-Complexed Aminophosphine Phosphinite Ligands for Highly Enantioselective Hydrogenation of α-functionalized Ketones,”Organometallics19 (2000) 5723-5732.
Peru Patent Office Technical Report PCG 66/1005/A, (2006).
Reed et al. “Structure—Activity Relationships of Cytotoxic Cholesterol-Modified DNA Duplexes,”J. Med Chem. 38 (1995) 4587-4596.
Schoenberg A. et al. “Palladium-Catalyzed Carboalkoxylation of Aryl, Benzyl, and Vinylic Halides,”J. Org. Chem. 39 (1974) 3318-3326.
Schoenberg et al., “Palladium-Catalyzed Amidation of Aryl, Heterocyclic, and Vinylic Halides,”J. Org. Chem. 39 (1974) 3327-3331.
Schultz et al., “Regio- and Stereoselective Control in the Addition of Grignard Reagents to the Pyridine Ring System,”J. Org. Chem. 51 (1986) 838-841.
Schultz, A. G. et al., “Enantioselective Method for Reductive Alkylation of Aromatic Carboxylic Acid Derivatives. Examination of the Factors that Provide Stereoselectivity.”Journal of the American Chemical Society110(23):7828-7841 (1988).
Sleevi M C et al., “Optical isomers of Rocastine and Close Analogues: Synthesis and H1 Antihistaminic Activity of its Enantiomers and their Structural Relationship to the Classical Antihistamines”; Journal of Medicinal Chemistry, American Chemical Society. Washington, US, vol. 34, No. 4, Apr. 1, 1991, pp. 1314-1328.
Thurston et al., “Synthesis and Reactivity of a Novel Oxazolo[2,3-c][1,4]benzodiazepine Ring System with DNA Recognition Potential: a New Class of Anthramycins,” J. Chem. Soc., Chem. Commun. (1990) 874-876.
Wolfe J.P. et al. “Simple, Efficient Catalyst System for the Palladium-Catalyzed Amination of Aryl Chlorides, Bromides, and Triflates,”J. Org. Chem. 65 (2000) 1158-1174.
Yamada, K.A., “Therapeutic Potential of Positive AMPA Receptor Modulators in the Treatment of Neurological Disease,”Exp. Opin. Invest. Drugs9 (2000) 765-778.
Yamada et al., “Diazoxide Blocks Glutamate Desensitization and Prolongs Excitatory Postsynaptic Currents in Rat Hippocampal Neurons,”J. Physiol458 (1992) 409-423.
Office Action Canadian Intellectual Property Office for Application No. 2,449,215 dated Jan. 21, 2010.
Office Action Canadian Intellectual Property Office for Application No. 2,449,215 dated Mar. 24, 2009.
Amendments/Remarks following Examiner's Report for USPN 2,449,215 dated Jul. 13, 2009.
Adam-Worrall Julia
Gilfillan Robert
Grove Simon James Anthony
Zhang Mingqiang
Devlin Gerard M.
Hess Susan L.
Kifle Bruck
N.V. Organon
LandOfFree
(Pyrido/thieno)-[f]-oxazepine-5-one derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with (Pyrido/thieno)-[f]-oxazepine-5-one derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and (Pyrido/thieno)-[f]-oxazepine-5-one derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4289133